Intranasal Foralumab for Multiple Sclerosis Now Approved by FDA for At-Home Dosing
October 20th 2023The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.
Read More